Company: GNMSF
Filing Date: 2025-08-07
Form Type: 6-K
Source: 0001434265-25-000063
Chunk: 8

Company: GENMAB A/S
Filing Date: 2025-08-07
Form: 6-K
Chunk 8
---
   |     |   |     |   |
| GEN1107              
 (PRO1107)            |     | Genmab                          |     | Protein tyrosine kinase 7 (PTK7)                                                                                           |     | ADC             |     | Advanced solid tumors                                                       |     |                                 |     |   |     |   |     |   |
| GEN1057              |     | Genmab                          |     | Fibroblast activation protein alpha (FAPα), death receptor 4 (DR4)                                                         |     | DuoBody         |     | Malignant solid tumors                                                      |     |                                 |     |   |     |   |     |   |
| GEN1286              
 (PRO1286)            |     | Genmab                          |     | Epidermal growth factor receptor (EGFR), cellular-mesenchymal epithelial transition factor receptor tyrosine kinase (cMET) |     | ADC             |     | Advanced solid tumors                                                       |     |                                 |     |   |     |   |     |   |

EPKINLY/TEPKINLY (epcoritamab) – the only bispecific antibody approved with a dual indication for the treatment of certain B-cell malignancies in the U.S., Europe and Japan

• Epcoritamab (approved as EPKINLY and TEPKINLY) has received regulatory approvals in multiple territories including in the U.S. and Europe for adult patients with relapsed or refractory DLBCL after two or more lines of systemic therapy, and in Japan for adult patients with certain types of relapsed or refractory LBCL after two or more lines of systemic therapy

• EPKINLY/TEPKINLY has also been approved in multiple territories including the U.S., Japan and Europe for the treatment of adults with relapsed or refractory FL after two or more lines of systemic therapy

• More than 40 clinical trials are ongoing across different treatment settings, lines of therapy and in combination regimens across histologies, including five Phase 3 trials and additional trials in development

• SC bispecific antibody targeting CD3 and CD20, created using Genmab’s DuoBody technology platform

• Co-developed and co-commercialized in collaboration with AbbVie

Epcoritamab is a proprietary bispecific antibody created using Genmab’s DuoBody technology platform. Epcoritamab targets CD3, which is expressed on T-cells, and